Amgen posts higher biosimilar sales, ends neuroscience program
(Reuters) – Amgen Inc on Tuesday said competition for its older drugs sent third-quarter revenue down 3%, but biosimilar sales…
Targeted Amgen drug has low response rate in colon cancer in study
(Reuters) – An experimental Amgen Inc drug that targets a specific genetic mutation shrank tumors in just one of 12…
Patent court to review Alexion’s Soliris patents on Amgen challenge
(Reuters) – The U.S. patent office will review patents on Alexion Pharmaceuticals Inc’s blood disorder treatment Soliris, after Amgen Inc…